These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10067696)

  • 1. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation.
    Kalus RM; Kantor JA; Gritz L; Gómez Yafal A; Mazzara GP; Schlom J; Hodge JW
    Vaccine; 1999 Feb; 17(7-8):893-903. PubMed ID: 10067696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity.
    Hodge JW; McLaughlin JP; Abrams SI; Shupert WL; Schlom J; Kantor JA
    Cancer Res; 1995 Aug; 55(16):3598-603. PubMed ID: 7543017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.
    Kantor J; Irvine K; Abrams S; Kaufman H; DiPietro J; Schlom J
    J Natl Cancer Inst; 1992 Jul; 84(14):1084-91. PubMed ID: 1619682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.
    Chamberlain RS; Carroll MW; Bronte V; Hwu P; Warren S; Yang JC; Nishimura M; Moss B; Rosenberg SA; Restifo NP
    Cancer Res; 1996 Jun; 56(12):2832-6. PubMed ID: 8665522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costimulatory molecules in vaccine design.
    Hodge JW; Schlom J
    Ernst Schering Res Found Workshop; 2000; (30):23-52. PubMed ID: 10943315
    [No Abstract]   [Full Text] [Related]  

  • 9. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
    Hodge JW; McLaughlin JP; Kantor JA; Schlom J
    Vaccine; 1997; 15(6-7):759-68. PubMed ID: 9178479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.
    Naito T; Kaneko Y; Kozbor D
    J Gen Virol; 2007 Jan; 88(Pt 1):61-70. PubMed ID: 17170437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
    Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
    Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
    Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
    Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
    Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7.
    Akagi J; Hodge JW; McLaughlin JP; Gritz L; Mazzara G; Kufe D; Schlom J; Kantor JA
    J Immunother; 1997 Jan; 20(1):38-47. PubMed ID: 9101412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
    Rao JB; Chamberlain RS; Bronte V; Carroll MW; Irvine KR; Moss B; Rosenberg SA; Restifo NP
    J Immunol; 1996 May; 156(9):3357-65. PubMed ID: 8617961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
    Hodge JW; Higgins J; Schlom J
    Vaccine; 2009 Jul; 27(33):4475-82. PubMed ID: 19450631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
    Kudo-Saito C; Hodge JW; Kwak H; Kim-Schulze S; Schlom J; Kaufman HL
    Vaccine; 2006 Jun; 24(23):4975-86. PubMed ID: 16621183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.
    Tsang KY; Zaremba S; Nieroda CA; Zhu MZ; Hamilton JM; Schlom J
    J Natl Cancer Inst; 1995 Jul; 87(13):982-90. PubMed ID: 7629885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
    Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
    Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines.
    Hodge JW; Schlom J
    Cancer Res; 1999 Oct; 59(20):5106-11. PubMed ID: 10537283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.